Current Headlines

  1. International Drug Companies Join BIO Ventures For Global Health To Tackle Cancer Crisis In Africa
    6/21/2017

    BIO Ventures for Global Health (BVGH), is launching the African Access Initiative (AAI) at 10:30 am recently at the Biotechnology Innovation Organization (BIO) International Convention at the San Diego Convention Center, Room 28AB, to address Africa’s emerging cancer crisis

  2. OncoArendi Therapeutics Announces Selection Of Its Second Clinical Development Candidate: OATD-02 For The Treatment Of Multiple Cancers
    6/21/2017

    OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate for cancer immunotherapy

  3. Tolero Pharmaceuticals To Expand Enrollment Of Phase II Study Of Alvocidib In MCL-1-Dependent AML Into Europe
    6/21/2017

    Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that it is adding European study centers to its ongoing Phase II clinical trial evaluating alvocidib in the U.S. and Canada for the treatment of MCL-1-dependent relapsed/refractory acute myeloid leukemia (AML)

  4. BioAuxilium Is Proud To Complete Development Of Its 100th TR-FRET Assay Kit For Drug Discovery And Life Science Research
    6/20/2017

    BioAuxilium Research Inc., a Canadian biotech specialized in the development of custom TR-FRET assay kits, announced recently at the 2017 BIO International Convention the successful development of its 100th custom TR-FRET immunoassay kit

  5. Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval Of Baxdela (Delafloxacin) For Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
    6/20/2017

    Ligand Pharmaceuticals Incorporated announces that partner Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, announced yesterday that the U.S. Food and Drug Administration (FDA) has approved Baxdela (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria

  6. twoXAR Announces Preclinical Proof-Of-Concept Data On Type 2 Diabetes Candidate
    6/19/2017

    twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, recently announced that its candidate, TXR-411, has shown promising results in the db/db mouse model of type 2 diabetes (T2DM)

  7. Syros Presents Discovery Of Key Genes Controlling The Autoimmune Response In Lupus In Late-Breaking Oral Presentation At FOCIS Meeting
    6/19/2017

    Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, recently announced that the Company has discovered alterations in regulatory regions of the genome in T cells from patients with systemic lupus erythematosus (SLE), revealing genes critical for activating T cells and driving disease

  8. Unum Therapeutics Announces Active Investigational New Drug (IND) Application For ACTR707 In Combination With Rituximab In Patients With Relapsed/Refractory B-cell Lymphoma
    6/19/2017

    Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, recently announced that an investigational new drug (IND) application for ACTR707 in combination with rituximab for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma, is now active

  9. Elsevier Launches Solution To Accelerate Drug Discovery Through Comprehensive Prediction And Assessment Of Drug-Drug Interactions
    6/19/2017

    Elsevier, the information analytics company specializing in science and health, has launched the PharmaPendium DMPK (Drug Metabolism-Pharmacokinetic) solution

  10. GNS Healthcare Announces Collaboration To Power Cancer Drug Development With REFS™ Causal Machine Learning And Simulation AI Platform
    6/19/2017

    GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancer therapies